Company Profiles

driven by the PitchBook Platform

Arsia Therapeutics

Description

Operator of a biopharmaceutical agency intended to develop innovative protein formulation. The company's biopharmaceutical agency produces high-concentration drugs and related products with low viscosity, suitable for small-volume subcutaneous injection, enabling clients to avail improved access to highly viscous protein therapeutics.

2013

Founded

M&A

Status

M&A

Latest Deal Type

$78M

Latest Deal Amount

Description

Operator of a biopharmaceutical agency intended to develop innovative protein formulation. The company's biopharmaceutical agency produces high-concentration drugs and related products with low viscosity, suitable for small-volume subcutaneous injection, enabling clients to avail improved access to highly viscous protein therapeutics.

Website:

www.arsiarx.com

Ownership Status

Acquired/Merged

Financing Status

Formerly VC-Backed

Primary Industry

Biotechnology

Other Industries

Pharmaceuticals
Drug Delivery

Primary Office

Kendall Square Cambridge, MA United States +1 (617) 863-3693
    Request a free trial to the PitchBook Platform
    You're viewing a free company profile from the PitchBook Platform. To explore Arsia Therapeutics's full profile, request a free trial.

    Arsia Therapeutics Valuation and Funding

    Request access
    Deal TypeDateAmountRaised to DatePost-ValStatusStage

    Arsia Therapeutics Executive Team (5)

    NameTitleBoard
    Seat
    Contact
    Info
    Kevin LoveDirector, Business Development & Operations
    Robert Langer Ph.DCo-Founder
    Charles Wescott Ph.DVice President of Research & Development
    Amy Schulman JDChief Executive Officer
    Alexander KlibanovCo-Founder
    Kevin Love Director, Business Development & Operations
    Robert Langer Ph.D Co-Founder
    Charles Wescott Ph.D Vice President of Research & Development
    Amy Schulman JD Chief Executive Officer
    Alexander Klibanov Co-Founder
    Request full access to PitchBook